FIELD: medicine.
SUBSTANCE: method involves determining acid alpha-1 glycoprotein and nitrogen oxide content at the time of disease exacerbation and at the moment the patient treatment being over. Acid alpha-1 glycoprotein content reduction being 1.5-1.6 times as high, and nitrogen oxide being 1.8-2.2 times as high, when compared to initial level, high treatment efficiency is considered to take place. Acid alpha-1 glycoprotein content reduction being 1.4-1.75 times as high, and nitrogen oxide being 1.4-1.75 times as high, when compared to initial level, low psoriatic erythrodermia treatment efficiency is considered to take place.
EFFECT: high accuracy of prognosis.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EVALUATING INFLAMMATORY PROCESS ACTIVITY AT PSORIASIS | 2005 |
|
RU2290645C1 |
| METHOD FOR ASSESSING THE EFFECTIVENESS OF TREATMENT OF PSORIATIC ARTHRITIS USING OXIDATIVE STRESS PARAMETERS | 2021 |
|
RU2762104C1 |
| METHOD FOR ESTIMATING PEMPHIGUS CLINICAL COURSE SEVERITY DEGREE | 2006 |
|
RU2316006C1 |
| METHOD FOR PREDICTING THE CHANCE FOR OSTEOMYELITIS CHRONIZATION IN CHILDREN | 2006 |
|
RU2304784C1 |
| METHOD FOR ESTIMATING INFLAMMATORY PROCESS ACTIVITY IN PEMPHIGUS CASES | 2006 |
|
RU2316003C1 |
| METHOD FOR ESTIMATING PEMPHIGUS TREATMENT EFFECTIVENESS | 2006 |
|
RU2316005C1 |
| METHOD OF ASSESSING INFLAMMATORY PROCESS ACTIVITY IN SARCOIDOSIS | 2010 |
|
RU2423701C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF AUTOIMMUNE PEMPHIGUS | 2010 |
|
RU2429482C1 |
| METHOD FOR TREATING PSORIASIS | 2004 |
|
RU2278660C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING TYPE 2 PSORIASIS IN POSTMENOPAUSAL WOMEN | 2018 |
|
RU2684287C1 |
